hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-07 and is reviewed periodically as new material appears.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
The energy associated with a particular wavefunction, perhaps the most important information contained in a wavefunction, can be extracted by solving the Schrödinger equation (above, Ψ is the wavefunction, E is the energy, and Ĥ is the Hamiltonian operator) in which an appropriate Hamiltonian operator is applied. In the various forms of the Schrödinger equation, the overall size of a particle's probability distribution increases with decreasing particle mass. For this reason, nuclei are of negligible size in relation to much lighter electrons and are treated as point charges in practical applications of quantum chemistry. Due to complex interactions which arise from electron-electron repulsion, algebraic solutions of the Schrödinger equation are only possible for systems with one electron such as the hydrogen atom, H2+, H32+, etc.; however, from these simple models arise all the familiar atomic (s,p,d,f) and bonding (σ,π) orbitals. In systems with multiple electrons, an overall multielectron wavefunction describes all of their properties at once. Such wavefunctions are generated through the linear addition of single electron wavefunctions to generate an initial guess, which is repeatedly modified until its associated energy is minimized. Thousands of guesses are often required until a satisfactory solution is found, so such calculations are performed by powerful computers. Importantly, the solutions for atoms with multiple electrons give properties such as diameter and electronegativity which closely mirror experimental data and the patterns found in the periodic table.
{\displaystyle {\begin{aligned}&{\frac {dS}{dt}}=-{\frac {\beta (t)IS}{N}}-v(t)S,\\[6pt]&{\frac {dI}{dt}}={\frac {\beta (t)IS}{N}}-\gamma (t)I,\\[6pt]&{\frac {dR}{dt}}=\gamma (t)I,\\[6pt]&{\frac {dV}{dt}}=v(t)S,\end{aligned}}}
A number of studies on the anatomical consistency of the image on the shroud and the nature of the wounds on it have been performed, following the initial study by Yves Delage in 1902. While Delage declared the image anatomically flawless, others have presented arguments to support both authenticity and forgery. The analysis of a crucified Roman, discovered near Venice in 2007, shows heel wounds that are consistent with those found on Jehohanan but which are not consistent with wounds depicted on the shroud. Also, neither of the crucifixion victims known to archaeology show evidence of wrist wounds. Joe Nickell in 1983 and Gregory S. Paul in 2010 separately state that the proportions of the image are not realistic, noting that the forehead on the shroud is too small and that the arms are too long and of different lengths. Nickell observed that the face and proportions of the shroud image are impossible, that the figure cannot represent that of an actual person and that the posture was inconsistent. Paul also noted the size of the forehead and distance from the eyebrows to the top of the head is abnormally low, making a cranial volume well below a human without severe pathological deformity (he compared it to that of a hominid from Late Pliocene to Early Pleistocene), which would necessarily cause a comparable intellectual disability. They concluded that the features can be explained if the shroud is a work of a Gothic artist following the standard conventions of his time. As Gregory S. Paul and Raymond E.
== Former supermarket chains == Carrefour (Taken over by AEON Group to become AEON BiG) Emporium Supermarket & Departmental Store Fajar Supermarket Hiong Kong Supermarket Jaya Supermarket Kimisawa Supermarket Makro (Taken over by Tesco to become Tesco Extra) Ngiu Kee Pasaraya Greatwall Pasaraya Ocean Rich Supermarket Senyum Supermarket Costco Sri Kota Supermarket Tesco (Taken over by Lotus's) Tesco Extra Tops Yaohan Supermarket Kedai Runcit Usaha Kami Yuyi Supermarket
Sources: en.wikipedia.org
== Creation and yield == The fissile isotope uranium-235 fuels most nuclear reactors. When 235U absorbs a thermal neutron, one of two processes can occur. About 85.5% of the time, it will fission; about 14.5% of the time, it will not fission, instead emitting gamma radiation and yielding 236U. Thus, the yield of 236U per 235U+n reaction is about 14.5%, and the yield of fission products is about 85.5%. In comparison, the yields of the most abundant individual fission products like caesium-137, strontium-90, and technetium-99 are between 6% and 7%, and the combined yield of medium-lived (10 years and up) and long-lived fission products is about 32%, or a few percent less as some are transmuted by neutron capture. The second-most used fissile isotope plutonium-239 can similarly fission or not on absorbing a thermal neutron, the latter giving plutonium-240, a major component of reactor-grade plutonium (plutonium recycled from spent fuel that was originally made with enriched natural uranium and then used once in an LWR). 240Pu decays with a half-life of 6561 years into 236U. In a closed nuclear fuel cycle, most 240Pu will fission (possibly after more than one neutron capture) before it decays, but 240Pu discarded as nuclear waste will decay over thousands of years. As 240Pu has a shorter half-life than 239Pu, the grade of any sample of plutonium mostly composed of those two isotopes will slowly increase, while the total amount of plutonium in the sample will slowly decrease over centuries and millennia.
=== Diabetes and pregnancy === A total review of metformin use during pregnancy compared to insulin alone found good short-term safety for both the mother and baby, but safety in the longer term is unclear. Several observational studies and randomized controlled trials found metformin to be as effective and safe as insulin for the management of gestational diabetes. Nonetheless, several concerns have been raised and evidence on the long-term safety of metformin for both mother and child is lacking. Compared with insulin, women with gestational diabetes treated with metformin gain less weight and are less likely to develop pre-eclampsia during pregnancy. Babies born to women treated with metformin have less visceral fat, and this may make them less prone to insulin resistance in later life. The use of metformin for gestational diabetes resulted in smaller babies compared to treatment with insulin. However, despite initially lower birth weight, children exposed to metformin during pregnancy had accelerated growth after birth, and were heavier by mid-childhood than those exposed to insulin during pregnancy. This pattern of initial low birth weight followed by catch-up growth that surpasses comparative children has been associated with long-term cardiometabolic disease. A systematic review and meta-analysis of metformin, published in 2024, found that it is safe and effective in managing gestational diabetes or diabetes in pregnancy with no adverse impact on the mother or the child after eleven years of childbirth.
=== Unnatural amino acid incorporation === Cell-free systems have also been used to incorporate unnatural amino acids. Shimizu et al. were able to change a stop codon to a sense codon by omitting the RF1 release factor, indicating ability to insert desired amino acids in unnatural situations. This is of use in systems where working inside a cell is problematic, such as the process of amino acid metabolism preventing specific labelling of amino acids that would be useful in multidimensional NMR spectroscopy. Kigawa et al.were able to successfully label amino acids in a cell-free system where amino acid metabolism was no longer present, thus making such systems useful to NMR studies.
This engagement is widely regarded in South Africa as the start of the Border War, and according to SWAPO, officially marked the beginning of its revolutionary armed struggle. Operation Blouwildebees triggered accusations of treachery within SWALA's senior ranks. According to SADF accounts, an unidentified informant had accompanied the security forces during the attack. Sam Nujoma asserted that one of the eight guerrillas from the second group who were captured in Kavangoland was a South African mole. Suspicion immediately fell on Leonard "Castro" Shuuya. SWALA suffered a second major reversal on 18 May 1967, when Tobias Hainyeko, its commander, was killed by the South African police. Heinyeko and his men had been attempting to cross the Zambezi River, as part of a general survey aimed at opening new lines of communication between the front lines in South West Africa and SWAPO's political leadership in Tanzania. They were intercepted by a South African patrol, and the ensuing firefight left Heinyeko dead and two policemen seriously wounded. Rumours again abounded that Shuuya was responsible, resulting in his dismissal and subsequent imprisonment. In the weeks following the raid on Omugulugwombashe, South Africa detained thirty-seven SWAPO politicians, namely Andimba Toivo ya Toivo, Johnny Otto, Nathaniel Maxuilili, and Jason Mutumbulua. Together with the captured SWALA guerrillas, they were jailed in Pretoria and held there until July 1967. All were charged retroactively under the Terrorism Act.
n orientation One of two possible orientations by which a linear DNA fragment can be inserted into a vector, specifically the one in which the gene maps of both fragment and vector have the same orientation. Contrast u orientation.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.